Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Next Previous
Drug Profile

Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Alternative Names: BDP/calcipotriene - MC2 Therapeutics; CAL/BDP - MC2 Therapeutics; Calcipotriol/betamethasone dipropionate - MC2 Therapeutics; MC2 01; MC2-01 PAD™ Cream - MC2 Therapeutics; MC2-14; PADcombo - MC2 Therapeutics; PADscalp - MC2 Therapeutics; Winxory; Wynzora

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Drug Delivery Solutions ApS
  • Developer Almirall S.A.; MC2 Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Interleukin 17 modulators; Interleukin 23 modulators; Steroid receptor agonists; Tumor necrosis factor-alpha expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis
  • Discontinued Psoriasis

Most Recent Events

  • 13 Mar 2024 Hyphens Pharma in-licenses betamethasone dipropionate/calcipotriol from MC2 Therapeutics for Plaque psoriasis in ASEAN countries
  • 09 Nov 2023 Launched for Plaque psoriasis in Italy (Topical) prior to November 2023
  • 31 Aug 2023 Hangzhou Zhongmei Huadong Pharmaceutical in-licenses betamethasone dipropionate/calcipotriol from MC2 Therapeutics for Plaque psoriasis in Greater China (Mainland China, Hong Kong, Macau and Taiwan)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top